Theravance Biopharma (0TB) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0TB Analyst Ratings

Hold

0 Buy

3 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Theravance

Biopharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0TB Stock 12 Month Forecast

Average Price Target

€14.75

▲(1.05% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Theravance Biopharma in the last 3 months. The average price target is €14.75 with a high forecast of €14.75 and a low forecast of €14.75. The average price target represents a 1.05% change from the last price of €14.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","13":"€13","18":"€18","10.5":"€10.5","15.5":"€15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.75396034,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€14.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.75396034,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€14.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.75396034,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,10.5,13,15.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,14.42722771846154,14.454455436923077,14.481683155384616,14.508910873846155,14.536138592307692,14.563366310769231,14.59059402923077,14.61782174769231,14.645049466153846,14.672277184615385,14.699504903076924,14.726732621538462,{"y":14.75396034,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,14.42722771846154,14.454455436923077,14.481683155384616,14.508910873846155,14.536138592307692,14.563366310769231,14.59059402923077,14.61782174769231,14.645049466153846,14.672277184615385,14.699504903076924,14.726732621538462,{"y":14.75396034,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,14.42722771846154,14.454455436923077,14.481683155384616,14.508910873846155,14.536138592307692,14.563366310769231,14.59059402923077,14.61782174769231,14.645049466153846,14.672277184615385,14.699504903076924,14.726732621538462,{"y":14.75396034,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€14.75

Average Price Target€14.75

Lowest Price Target€14.75

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

€14.75

Hold

1.05%

Upside

Downgraded

07/07/26

Theravance Biopharma downgraded to Neutral from Buy at H.C. WainwrightTheravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright

Julian Harrison

BTIG

―

Hold

―

Downgraded

06/29/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Theravance Biopharma (NASDAQ: TBPH)

Debanjana Chatterjee

JonesTrading

€16.49→€14.75

Hold

1.05%

Upside

Downgraded

06/29/26

Theravance Biopharma downgraded to Hold from Buy at JonesResearchTheravance Biopharma downgraded to Hold from Buy at JonesResearch

Marc Frahm

TD Cowen

€13.02

Hold

-10.83%

Downside

Assigned

05/08/26

Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target

Mayank Mamtani

B. Riley Securities

€12.15→€14.75

Hold

1.05%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Theravance Biopharma (NASDAQ: TBPH)

Trevor Allred

Oppenheimer

€23.43→€11.86

Hold

-18.74%

Downside

Downgraded

03/05/26

Theravance Biopharma downgraded to Perform from Outperform at OppenheimerTheravance Biopharma downgraded to Perform from Outperform at Oppenheimer

David Risinger

Leerink Partners

€8.68→€11.28

Hold

-22.72%

Downside

Reiterated

08/13/25

Leerink Partners Reaffirms Their Hold Rating on Theravance Biopharma (TBPH)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

€14.75

Hold

1.05%

Upside

Downgraded

07/07/26

Theravance Biopharma downgraded to Neutral from Buy at H.C. WainwrightTheravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright

Julian Harrison

BTIG

―

Hold

―

Downgraded

06/29/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Theravance Biopharma (NASDAQ: TBPH)

Debanjana Chatterjee

JonesTrading

€16.49→€14.75

Hold

1.05%

Upside

Downgraded

06/29/26

Theravance Biopharma downgraded to Hold from Buy at JonesResearchTheravance Biopharma downgraded to Hold from Buy at JonesResearch

Marc Frahm

TD Cowen

€13.02

Hold

-10.83%

Downside

Assigned

05/08/26

Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target

Mayank Mamtani

B. Riley Securities

€12.15→€14.75

Hold

1.05%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Theravance Biopharma (NASDAQ: TBPH)

Trevor Allred

Oppenheimer

€23.43→€11.86

Hold

-18.74%

Downside

Downgraded

03/05/26

Theravance Biopharma downgraded to Perform from Outperform at OppenheimerTheravance Biopharma downgraded to Perform from Outperform at Oppenheimer

David Risinger

Leerink Partners

€8.68→€11.28

Hold

-22.72%

Downside

Reiterated

08/13/25

Leerink Partners Reaffirms Their Hold Rating on Theravance Biopharma (TBPH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Theravance Biopharma

3 Months

DeepSeek BiotechnologyTipRanks - DeepSeek

Success Rate

2/3 ratings generated profit

Average Return

-4.13%

Copying DeepSeek Biotechnology's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -4.13% per trade.

1 Year

DeepSeek BiotechnologyTipRanks - DeepSeek

Success Rate

2/3 ratings generated profit

Average Return

-2.73%

Copying DeepSeek Biotechnology's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -2.73% per trade.

2 Years

DeepSeek BiotechnologyTipRanks - DeepSeek

Success Rate

2/3 ratings generated profit

Average Return

-2.73%

Copying DeepSeek Biotechnology's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of -2.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0TB Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0TB has received 0 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0TB average Analyst price target in the past 3 months is 14.75.

Each month's total comprises the sum of three months' worth of ratings.

0TB Financial Forecast

0TB Earnings Forecast

Next quarter’s earnings estimate for 0TB is €0.19 with a range of €0.07 to €0.26. The previous quarter’s EPS was -€0.10. 0TB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.33% of the time in the same period. In the last calendar year 0TB has Performed in-line its overall industry.

0TB Sales Forecast

Next quarter’s sales forecast for 0TB is €19.01M with a range of €18.36M to €19.92M. The previous quarter’s sales results were €17.96M. 0TB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.21% of the time in the same period. In the last calendar year 0TB has Performed in-line its overall industry.

0TB Stock Forecast FAQ

What is DE:0TB’s average 12-month price target, according to analysts?

Based on analyst ratings, Theravance Biopharma’s 12-month average price target is 14.75.

What is DE:0TB’s upside potential, based on the analysts’ average price target?

Theravance Biopharma has 1.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Theravance Biopharma a Buy, Sell or Hold?

Theravance Biopharma has a consensus rating of Hold, which is based on 0 buy ratings, 3 hold ratings and 0 sell ratings.

What is Theravance Biopharma’s share price target?

The average share price target for Theravance Biopharma is 14.75. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €14.75 ,and the lowest forecast is €14.75. The average share price target represents 1.05% Increase from the current price of €14.6.

What do analysts say about Theravance Biopharma?

Theravance Biopharma’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Theravance Biopharma?

To buy shares of DE:0TB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Theravance Biopharma (0TB) Stock Forecast & Price Target

0TB Analyst Ratings

0TB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Theravance Biopharma

0TB Analyst Recommendation Trends

0TB Financial Forecast

0TB Earnings Forecast

0TB Sales Forecast

0TB Stock Forecast FAQ

Detailed List of Analyst Forecasts